Understanding Biological Processes

Just out in Science (2025)—a landmark study by Christina Jackson et al. identifies a previously uncharacterized immune cell population in human glioblastoma (GBM), termed early myeloid-derived suppressor cells (E-MDSCs). (Michael Lim, CHETAN BETTEGOWDA, Hongkai Ji, Drew Pardoll) These E-MDSCs uniquely infiltrate IDH-wild-type GBM, precisely colocalizing with glioma stem-like cells (GSCs) within pseudopalisading regions—distinct zones known for hypoxia, aggressive invasion, and treatment resistance. Strikingly, the authors uncovered a novel bidirectional signaling axis: GSCs recruit E-MDSCs by secreting specific chemokines, while E-MDSCs reciprocate by releasing potent growth factors (notably FGF11) that drive tumor proliferation via the FGF11-FGFR1 signaling pathway. Importantly, this critical tumor–immune interaction is entirely absent in IDH-mutant gliomas, due to epigenetic silencing of essential chemokine genes. This discovery not only advances our fundamental understanding of glioblastoma biology but also highlights promising new therapeutic targets specifically tailored for IDH-WT GBM—opening a vital new chapter in treating this notoriously aggressive and therapy-resistant cancer. Penn Medicine, University of Pennsylvania Health System, Johns Hopkins Medicine, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins Kimmel Cancer Center

Your immune system is not mine. And that changes everything. Exposed to the same virus, each of us produces a distinct antibody profile. Not just in quantity, but in precision: the regions of the virus we target, the proteins we recognize, the memory we build. Age, biological sex and genetics reach into the very architecture of how we respond to infections. A study just published in Nature Immunology, from teams at Institut Pasteur, CNRS and the Collège de France, makes this strikingly clear — and speaks directly to one of Pasteur 2030's growing research priorities: understanding how individual biological factors shape immunity and what that means for human health. The study analyzed antibodies from 1,000 healthy individuals against more than 90,000 viral protein fragments. Age alone accounts for over half of the variation in our antibody repertoire. Against influenza H1N1 and H3N2, younger adults target the variable surface of the virus while older individuals shift toward its stable core. Women and men mount different responses to the same flu strains, despite comparable vaccination rates. And against a shared pathogen, European and African cohorts produce antibodies targeting entirely different proteins — shaped by geography and exposure history. Each body writes its own immunological story. For decades, we have designed vaccines and treatments as if immune responses were universal. Integrating this variability — across individuals, populations, and geographies underrepresented in global research — is a rethinking of medicine's foundations. Congratulations to Lluis Quintana-Murci and all the teams behind this landmark work. #Immunology #Vaccines #PersonalizedMedicine 

Gut bacterium may be helping breast tumors hide from the immune system. And it appears to do it through a metabolite. Researchers found that Enterocloster bolteae, a member of the Lachnospiraceae family, became progressively more abundant as breast tumors developed. Its rise was linked to higher levels of deoxycholic acid, a secondary bile acid produced through microbial metabolism. But the metabolite did not remain confined to the gut. Deoxycholic acid accumulated inside the tumors and activated the farnesoid X receptor, or FXR, in cancer cells. That activation triggered NF-κB signaling and increased production of interleukin-6. IL-6 then recruited immune cells that can suppress antitumor immunity, including granulocytic myeloid-derived suppressor cells and T helper 17 cells. The result was a tumor microenvironment that appeared more capable of protecting the cancer from immune attack. The pathway looked like this: Enterocloster bolteae → deoxycholic acid → tumor FXR activation → NF-κB signaling → IL-6 production → immunosuppressive immune-cell recruitment → breast cancer progression This is more than another study showing that cancer is “associated” with changes in the microbiome. It proposes a specific biological chain connecting a gut organism, a circulating microbial metabolite, a receptor inside the tumor and a measurable immune response. Even more importantly, blocking FXR or IL-6 signaling weakened these effects in the experimental models. That creates several potential intervention points. Not just the bacterium itself, but its metabolic output, the tumor receptor it activates and the downstream inflammatory signal. This does not mean that modifying the microbiome can currently prevent or treat breast cancer. But it strengthens a much bigger idea: The gut microbiome may influence cancer progression from a distance by producing molecules that reach the tumor and reshape its immune environment. The next generation of cancer therapeutics may not focus only on the tumor. It may also target the microbial chemistry helping the tumor survive.

Stanford scientists have discovered that cancer cells don’t just use one trick to hide from the immune system—they use two separate “don’t-eat-me” signals to stop macrophages from killing them. The first signal, CD47, was already famous for acting like an invisibility cloak that tells macrophages to back off, and blocking it with an anti-CD47 antibody is already in human trials. In the Nature Immunology paper, the same Stanford team also found that tumors use MHC class I as a second stop signal by binding to a macrophage receptor called LILRB1, which suppresses the macrophage’s ability to engulf and destroy the cancer. When researchers blocked both CD47 and LILRB1 in mice, tumors rapidly filled with immune cells, shrank significantly, and became far easier for the body to clear. This shows that many cancers survive by running two overlapping escape systems, and turning off both “don’t-eat-me” pathways at once may dramatically boost the immune system’s ability to attack and eliminate tumors.

📢 Excited to share our latest research published in Nature: "A human brain map of mitochondrial respiratory capacity and diversity"! 🔬 In collaboration with an exceptional team, we've developed an innovative approach to bridge cellular biology and cognitive neuroscience by mapping mitochondrial function across the human brain at neuroimaging resolution. 🧠 Key findings: Grey matter contains >50% more mitochondria than white matter. Mitochondria in recently evolved cortical areas exhibit specialized energy-transforming capabilities, aligning with the metabolic demands of human-specific cognitive functions. We created MitoBrainMap, a brain-wide atlas predicting mitochondrial characteristics from MRI data. 🌟 This work opens new avenues for understanding the mitochondrial basis of normal brain function and its implications for neurodegenerative, neurovascular and neuropsychiatric conditions. Explore the interactive MitoBrainMap here 👉 https://lnkd.in/dRiwBJex Full article: https://lnkd.in/dzS2zkMS Grateful to all collaborators and institutions involved! VBHI Columbia University CNRS Bordeaux University #Neuroscience #Mitochondria #BrainMapping #MRI #NaturePublication

"We've run out of options." Five words no patient wants to hear. Triple-negative breast cancer. Pancreatic adenocarcinoma. The cancers that shrug off treatment—where chemo buys time but rarely wins. For decades, the playbook was blunt: hit fast-growing cells and hope the tumor breaks before the body does. The tradeoff was brutal—nausea, hair loss, infections—and patients paid it anyway. Stanford researchers tried a different angle: instead of attacking the tumor directly, deliver an immune trigger to the neighborhood around it. Tumors often sit inside an immunosuppressive microenvironment. The immune system is nearby, but shut down. The Stanford team built a synthetic molecule that targets integrins overexpressed on tumors and delivers an immune activator directly to the site. What they saw: ↳ T-cells and other immune cells moved into the tumor ↳ The local immune response switched back on ↳ Significant tumor regression after 3 IV treatments ↳ Fewer off-target effects than traditional chemo This isn't a cure. It's preclinical. The team is still improving stability ahead of human trials. They're also testing it with checkpoint inhibitors—aiming for immune memory that could help prevent recurrence. But the direction matters. The Multiplication Effect: 1 molecule that works = validates the approach 10 patients in trials = shows whether it holds up 100 oncologists adopting it = a new standard for the hardest cancers At scale = fewer people hearing "we've run out of options" For a century, we tried to beat cancer by burning it down. Maybe the better move is to help the body fight. Follow me, Dr. Martha Boeckenfeld for Insights on thriving when AI rises, but Leaders stay Human. Sources: Stanford University, Cell Chemical Biology (2021)

🧠 As a neuroscientist, I find this absolutely incredible. The first-ever atlas of brain development has just been published and it’s nothing short of breathtaking. For the first time, researchers have mapped how stem cells transform into neurons during mammalian brain development, tracking hundreds of thousands of cells in humans and mice. They’ve identified when and how neural progenitors shift from building excitatory to inhibitory neurons and even how glial cells emerge over time. In essence, they’ve charted the biological choreography of the brain’s birth. This isn’t just a technical feat. It’s a window into the deepest question in neuroscience: ➡️ How does a collection of stem cells become a mind? Projects like the BRAIN Initiative Cell Atlas Network (BICAN) are changing how we understand neurodevelopment, disorders like autism and schizophrenia, and even how we model the brain in vitro. Every data point in this atlas carries potential for precision medicine, regenerative neuroscience, and the next generation of brain-inspired models. Truly a landmark moment. What a time to be doing neuroscience. 🧬 #Neuroscience #BrainDevelopment #StemCells #BRAINInitiative #Neurogenesis #Nature #ScientificDiscovery #Neurobiology

A groundbreaking development in biohybrid robots has brought us closer to creating machines powered by real human muscle cells. Researchers, led by Shoji Takeuchi from Tokyo University, have built a full-size robotic hand, complete with five fingers, using lab-grown human muscle tissue. This innovative biohybrid hand is powered by muscle fibers that are cultured, rolled into tubes, and then electrically stimulated to create movement. Known as MuMuTAs, these muscle tubes are designed to mimic the contraction and movement of natural muscles, overcoming past challenges with maintaining muscle health in robotic systems. The process behind making these muscle tubes involves growing thin muscle sheets and rolling them into cylindrical shapes, much like sushi rolls. This technique ensures that the cells get the oxygen and nutrients they need, which is crucial to avoid cell death (necrosis) in thicker muscle structures. The MuMuTAs are activated with electrical signals, making them capable of bending, rotating, and generating enough force to perform tasks like playing rock-paper-scissors or even manipulating objects like pipettes. Each MuMuTA can generate 8 mN of force, enough to lift light objects. However, the team faced challenges. For example, the hand's fingers could only move in one direction, and the hand relied on a liquid suspension to keep the muscles functioning. Plus, the muscles fatigued after just 10 minutes of use, highlighting a need for further development. The next steps will involve improving muscle endurance and creating systems to keep the muscles alive outside the liquid medium. Research Paper 📄 https://lnkd.in/e8hweZZR

💬 "If you don't have celiac disease, you don't need to avoid gluten." If only you had a dime for every time a healthcare provider said this. It turns out that celiac disease isn't the only autoimmune condition that can be caused or exacerbated by gluten consumption. 🧬 Celiac disease is considered a hereditary genetic condition, characterized by the presence of certain genetic alleles such as HLA-DQ2 and HLA-DQ8. But several other autoimmune diseases are also linked to gluten sensitivity, including type 1 diabetes, rheumatoid arthritis, and Sjögren's syndrome. 🍏 Nutrigenomics provides a genetic understanding for how common dietary components, such as gluten, affect our health and disease status. Let’s examine the interplay between gluten and various genes associated with autoimmune conditions. The genes implicated in these conditions fall into three main categories: 1️⃣ HLA genes (in pink): These are part of our immune system and play a crucial role in how our bodies recognize and respond to foreign substances, including gluten. Examples include: 📌 HLA-DQ2 and HLA-DQ8: Strongly associated with celiac disease 📌 HLA-DR3 and HLA-DR5: Linked to autoimmune thyroid diseases 2️⃣ Non-HLA genes (in blue): These include genes involved in immune regulation, intestinal barrier function, and cellular processes that can influence autoimmune responses. Examples include: 📌 IL-2 and IL-21: Involved in regulating immune responses 📌 INS: Insulin gene, associated with type 1 diabetes 📌 FOXP3: Important for the function of regulatory T cells 3️⃣ Shared genes (in orange): These genes are associated with multiple autoimmune conditions, suggesting common pathways in autoimmune dysfunction. Examples include: 📌 CTLA4: Regulates T cell responses & linked to several autoimmune diseases 📌 STAT4: Involved in immune cell signaling & associated with multiple autoimmune conditions 📌 MYO9B: Affects intestinal permeability & linked to celiac disease, rheumatoid arthritis, and lupus While not everyone with these genes will develop gluten sensitivity or an autoimmune condition, this research is a reminder that nutrition isn't one-size-fits-all, and some individuals might benefit from reducing gluten intake even in the absence of celiac diagnosis. Always consult with a healthcare professional before making significant dietary changes, but don't be afraid to advocate for yourself if you suspect gluten sensitivity. Your body's response to food is unique, and recognizing that is key to improving health outcomes.

The mechanism by which T cells destroy cancer cells is a crucial part of the body's immune response. Specifically, Cytotoxic T lymphocytes (CTLs), a type of CD8+ T cell, play a major role in recognizing and eliminating cancer cells. The process involves the following steps: 1. Recognition of Cancer Cells Antigen Presentation: Cancer cells present abnormal proteins (tumor antigens) on their surface using Major Histocompatibility Complex (MHC) Class I molecules. T Cell Receptor (TCR) Binding: CD8+ T cells recognize these tumor antigens through their T cell receptors (TCRs), initiating an immune response. Co-stimulation: Additional signals from molecules like CD28 and CD80/86 help activate T cells fully. 2. Activation and Proliferation Once activated, T cells proliferate and differentiate into cytotoxic T lymphocytes (CTLs), which are specialized in killing cancer cells. 3. Killing Mechanisms Cytotoxic T cells use two major mechanisms to destroy cancer cells: (A) Perforin-Granzymes Pathway CTLs release perforin, a protein that forms pores in the cancer cell membrane. Through these pores, granzymes (proteolytic enzymes) enter the cancer cell. Granzymes trigger apoptosis (programmed cell death) by activating caspases, leading to DNA fragmentation and cell death. (B) Fas-Fas Ligand (FasL) Pathway CTLs express Fas ligand (FasL), which binds to Fas receptors (CD95) on cancer cells. This interaction activates the caspase cascade, leading to apoptosis. 4. Immune Checkpoint Regulation Cancer cells can evade T cell attacks by expressing immune checkpoint proteins like PD-L1 (Programmed Death-Ligand 1), which binds to PD-1 (Programmed Death-1) on T cells and suppresses their function. Checkpoint inhibitors (like anti-PD-1 or anti-CTLA-4 antibodies) are used in immunotherapy to block these signals and restore T cell activity. 5. Memory T Cell Formation Some T cells differentiate into memory T cells, which provide long-term immunity by recognizing and responding faster if the cancer reappears. This T cell-mediated immune response is the foundation of cancer immunotherapy, where strategies like CAR-T cell therapy, checkpoint inhibitors, and cancer vaccines enhance the body's natural ability to fight cancer. #manojpatra #tcell #cancer #cancerawarness #cancertreatment